Announcements Trials
Browse Landscape

Phase

Phase 3 3Phase 1 3Phase 2 2

Status

Completed 2Recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 3

Conditions

Leukemia, Myeloid, Acute 5Leukemia 3

Interventions

Cytarabine 68Cyclophosphamide 44Methotrexate 41Daunorubicin 38Etoposide 34Vincristine 30Mercaptopurine 28Dexamethasone 24Radiotherapy 22Idarubicin 22Asparaginase 21Thioguanine 20Doxorubicin 19Prednisone 17Peripheral Blood Stem Cell Transplantation 17Imatinib Mesylate 16Busulfan 16pegaspargase 15Mitoxantrone 15Filgrastim 13Leucovorin 11fludarabine phosphate 10Hydrocortisone 10nilotinib 9Tretinoin 8Prednisolone 8Cyclosporine 8Hydroxyurea 7Epoetin Alfa 7Azacitidine 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Leukemia × quizartinib × Clear all
NCT06578247 2026-04-30

QuANTUM-WILD

Daiichi Sankyo

Phase 3 Recruiting
700 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02668653 2024-08-06

QuANTUM-First

Daiichi Sankyo

Phase 3 Completed
539 enrolled 20 charts 1 FDA
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

NCT02039726 2021-02-24

(QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

Daiichi Sankyo

Phase 3 Completed
367 enrolled 12 charts
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡